19.9500.75% ( -0.150 )
Delay Closed: Nov 17, 16:08:15Valuation
Current ValuationThe current P/E ratio is -8.56, above the reasonable range, cheaper than 17.31% of the time in the past 1 years, and the industry ranks 43/53, the industry Median 6.96.
-8.56xP/E
HK$19.95Stock price
HK$-2.33Earnings per share
-8.56xP/E
Stock priceHK$19.95Earnings per shareHK$-2.33
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -11.40x
- Typical range
- -13.44x–-8.85x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 6.96x
010203040
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 6.96x
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
06887HKSUNSHINE PHARMA | -63.90x | -- | HK$20.96B |
02630HKVIGONVITA-B | -35.68x | -- | HK$12.52B |
09637HKALEBUND-B | -8.56x | 48.51% | HK$6.94B |
00570HKTRAD CHI MED | -4.85x | 223.71% | HK$5.64B |
02575HKXUANZHUBIO-B | -17.24x | -- | HK$4.17B |
01477HKOCUMENSION-B | -27.28x | 52.42% | HK$3.94B |
01349HKFUDANZHANGJIANG | -19.59x | -- | HK$2.35B |
02552HKHUA MEDICINE-B | -17.58x | 104.78% | HK$2.18B |
02652HKCF PHARMTECH | -256.41x | -- | HK$2.00B |
06622HKZHAOKE OPHTH-B | -4.47x | -- | HK$1.11B |
01652HKFUSEN PHARM | -224.00x | -- | HK$598.83M |
01011HKNT PHARMA | -15.28x | -- | HK$485.07M |
01643HKMODERN CHI MED | -6.71x | -- | HK$324.00M |
00575HKREGENT PACIFIC | -14.11x | -- | HK$215.94M |
08329HKNEP INTERLONG | -3.48x | -- | HK$211.43M |
01312HKKONTA CHINA | -0.76x | -- | HK$162.07M |
00455HKTIANDA PHARMA | -2.34x | -- | HK$161.25M |
00858HKEXTRAWELL PHAR | -0.16x | -- | HK$159.50M |
01498HKPURAPHARM | -4.17x | -- | HK$115.22M |
01889HKSANAI HEALTH GP | -1.01x | -- | HK$22.63M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
